...
首页> 外文期刊>Genome Biology >The road to drug resistance in Mycobacterium tuberculosis
【24h】

The road to drug resistance in Mycobacterium tuberculosis

机译:结核分枝杆菌的耐药性之路

获取原文

摘要

Sequencing of serial isolates of extensively drug-resistant tuberculosis highlights how drug resistance develops within a single patient and reveals unexpected levels of pathogen diversity. Tuberculosis (TB) remains a crucial public health problem, with increasing drug resistance posing a challenge to current control efforts. Treatment regimens for drug-susceptible TB are onerous, requiring a minimum of six months of treatment with four antitubercular drugs. There are patients who develop multi-drug-resistant (MDR), extensively drug-resistant (XDR) and totally drug-resistant (TDR) forms, which are successively more difficult to treat. In these circumstances, treatment regimens involve the use of a larger number of less-effective drugs, which have a narrower therapeutic margin. In many bacteria, drug-resistance determinants are carried on mobile genetic elements. However, in Mycobacterium tuberculosis (Mtb), drug resistance is exclusively associated with point mutations and chromosomal rearrangements. Poor or intermittent therapy has long been thought to be the major explanation for drug resistance, and it is believed that drug-resistant strains develop through the sequential fixation of a small set of mutations, such that the pathogen samples only a small proportion of possible evolutionary paths [1]. The application of whole-genome sequencing (WGS) has revealed previously underappreciated levels of genetic diversity within circulating Mtb populations, and the implications of this diversity for transmission and disease outcomes are increasingly being acknowledged. By contrast, mycobacterial heterogeneity within a single host, and any concomitant biological or clinical significance, has been explored but seldom documented. In a study published in this issue of Genome Biology, Eldholm and colleagues apply WGS to investigate the evolution from drug-sensitive to XDR-TB within a single patient [2]. This adds to an emerging body of evidence that suggests that intra-host microbial diversity is substantial and might have significant consequences when inferring transmission. There are few instances, if any, in the literature where this has been investigated in such detail.
机译:广泛耐药结核病系列分离株的测序突出显示了单例患者体内耐药性的发展,并揭示了病原体多样性的意外水平。结核病(TB)仍然是至关重要的公共卫生问题,耐药性的提高对当前的控制工作提出了挑战。药物敏感性结核病的治疗方案繁重,需要使用四种抗结核药物至少治疗六个月。有些患者会发展出多重耐药性(MDR),广泛耐药性(XDR)和完全耐药性(TDR)形式,这些形式相继难以治疗。在这些情况下,治疗方案涉及使用大量疗效较差的疗效较差的药物。在许多细菌中,耐药性决定簇被携带在可移动的遗传元件上。但是,在结核分枝杆菌(Mtb)中,耐药性仅与点突变和染色体重排有关。长期以来,人们一直认为不良或间歇性治疗是耐药性的主要解释,人们认为耐药菌株是通过顺序固定一小部分突变而形成的,因此病原体样本仅占很小一部分可能的进化路径[1]。全基因组测序(WGS)的应用揭示了以前循环的Mtb种群中遗传多样性的水平未得到充分重视,这种多样性对传播和疾病后果的影响日益得到人们的认可。相比之下,已经探讨了单个宿主内的分枝杆菌异质性以及任何伴随的生物学或临床意义,但很少有文献记载。在本期《基因组生物学》上发表的一项研究中,Eldholm及其同事应用WGS研究了单例患者从药物敏感性到XDR-TB的演变[2]。这增加了一个新兴的证据,表明宿主内部的微生物多样性是巨大的,并且在推断传播时可能会产生重大后果。在文献中很少有这样的情况被详细研究过。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号